ClinicalTrials.gg
Not yet recruitingNCT07850804NASHA-DXUpdated Sep 30, 2026

Trial of NASHA Dx Urethral Bulking System

An interventional study of NASHA Dx and Bulkamid in Urinary Incontinence, Urinary Incontinence (UI) and Urinary Incontinence , Stress, sponsored by Palette Life Sciences, Inc.. Not yet recruiting at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionUrinary Incontinence, StressRegistry: Urinary IncontinenceReclassifiedWhy we changed it
Registry
Urinary Incontinence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Incontinence, Stress
Why
  1. The study's listed conditions name Urinary Incontinence, Stress, a narrower term within Urinary Incontinence.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Palette Life Sciences, Inc. · Not applicable, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.

Planned enrollment
27th of 163
314 · median 98
Started
2026
with 4 others
No phase
109 of 189
18 open now
Primary completion
2027-09
later than 24 of 39 live
Registered
189th of 189
by date

Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 27th largest by planned enrollment of the 163 interventional ones that give a count, is one of 5 that started in 2026, is one of 109 with no phase, reaches primary completion later than 24 of the 39 other live ones, and was the 189th registered.

Urinary Incontinence, Stress

653 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Incontinence, Stress studies recruiting now, 42 (56%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

Prospective, randomized, single-blind study to evaluate the safety and efficacy of NASHA Dx investigational device compared to controlled device Bulkamid in adult women with mild, moderate and intrinsic sphincter deficiency (ISD).

Read the detailed description

This is a prospective, randomized, single-blind study. The primary cohort for this study is adult women with mild, moderate and intrinsic sphincter deficiency (ISD) stress or stress urinary incontinence (SUI) or stress predominant mixed incontinence (MUI).

After preliminary screening, subjects who sign an informed consent and are enrolled in the study will be randomized to the Investigational device (NASHA Dx) group or the Control device (Bulkamid) group. Subjects will not be told which treatment they will receive.

03

Conditions studied

  • Urinary Incontinence
  • Urinary Incontinence (UI)
  • Urinary Incontinence , Stress
  • Urinary Incontinence Due to Urethral Sphincter Incompetence
  • Urethral Sphincter Activity
  • Intrinsic Sphincter Deficiency
  • Pelvic Floor Dysfunction

Browse trials for

Keywords

  • Urethral Bulking Agents
04

In context

Urinary Incontinence, Stress Reclassified

653 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

This study's planned enrollment of 314 is above the median of 68 across 508 interventional studies indexed under Urinary Incontinence, Stress.

Browse Urinary Incontinence, Stress studies →

Lead sponsor

Palette Life Sciences, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Compared within Urinary Incontinence, Stress, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Incontinence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 1. Female, ≥ 18 years of age
  2. All women of must have a negative urine pregnancy test result documented prior to inclusion into the trial at Screening.
  3. SUI or stress predominant mixed urinary incontinence due to intrinsic sphincter deficiency (ISD) for at least 6 months
  4. Failed conservative therapy for stress urinary incontinence
  5. Documentation of at least 3 stress urinary incontinence episodes measured over 3 days
  6. Baseline 24-hr. pad weight test ≥ 5 g
  7. Intrinsic sphincter deficiency stress urinary incontinence defined as a urodynamic assessment in the past 6 months with Valsalva leak-point pressure (VLPP) \< 60 cm H2O and/or a maximal urethral closure pressure (MUCP) 20 cm H2O
  8. Clinical laboratory values such as white blood cell count, , /ALT, Creatinine, , blood glucose are within normal limits, or if abnormal, considered and documented as not by the investigator
  9. Cleared for surgery by anesthesiologist preoperatively
  10. of more than 2 years
  11. Been informed of, and be able to perform, the study treatments and procedures, and signed an form.
  12. Provided authorization to use and disclose information for research purposes [HIPAA (Health Insurance Portability and Accountability Act of 1996; US sites) or country-specific requirement]

Exclusion criteria

Exclusion Criteria:

  1. 1. Urgency Predominant Mixed urinary incontinence, confirmed by 3-day bladder diary. (greater than 50% of incontinence episodes due to urge or less than 50% of incontinence episodes due to stress).
  2. Negative cough test or lack of leakage with valsalva maneuver on physical exam
  3. Historical Detrusor overactivity as determined by urodynamic assessment within the past year
  4. Significant urethral hypermobility (e.g. vaginal swab > 30° from horizontal bladder neck)
  5. History of urethral bulking, artificial urinary sphincters and previous urethral surgery for incontinence or non-incontinence related indications (eg. fistulas or diverticula) are not permitted
  6. Patient may not have undergone a Mid-Urethral Sling (MUS), retropubic colpo or pubovaginal sling less than 6 months from screening
  7. Polyuria (≥ 3 L/24 hrs.)
  8. Three or more culture proven bacterial UTIs in the last 12 months or 2 culture proven bacterial UTIs in the last 6 months
  9. Current urogenital infection: urethritis, cystitis, urinary tract infection or vaginitis
  10. Unevaluated hematuria
  11. No prolapse through the introitus at screening visit
  12. (BMI) > 35 kg/m2
  13. Currently taking or has taken within 4 weeks prior to the screening/baseline visit, pharmacological treatment for Overactive Bladder (OAB) (including but not limited to anti-cholinergics or beta adrenergics)
  14. Allergy to hyaluronic acid-based products or dextran or history of severe allergies or anaphylaxis including to local anesthetics such as lidocaine or antibiotics used for treating urinary tract infections
  15. Active diseases (e.g., connective tissue diseases) that could affect or confound treatment outcome
  16. Systemic - currently taking, or has taken, within 3 months prior to the initial treatment visit
  17. Currently has cancer or has a history of cancer within the past 5 years. Subjects with a history of skin cancer with no evidence of skin for less than 2 years, will be excluded. Note: basal cell carcinoma is not an exclusion criterion
  18. Any unstable or severe cardio-vascular disease
  19. Uncontrolled diabetes defined as greater than 8% within the prior 6 months or at screening. Note: Patients with suspected or known diabetes mellitus type II who lack an HbA1c result within the past 6 months will have a random glucose test at screening and a HbA1c test at screening. Patients with blood glucose >180 mg/dL will be excluded or HbA1c of 8% or greater will be excluded
  20. Active herpes genitalis (lesion, prodrome, symptoms)
  21. Currently participating in any other clinical trial or has participated in another clinical trial within 3 months prior to the screening/baseline visit, where the outcome measures may overlap.
  22. History of drug/alcohol abuse, mental dysfunction health condition, or other factors limiting her ability to cooperate fully
  23. Pregnant, lactating, or not practicing adequate (refer to inclusion criteria), was intending to become pregnant, or to lactate for the duration of this study (approximately 12 months)
  24. Not physically able to perform study procedures
  25. Bladder dysfunction in the setting of known neurologic disease that negatively impacts bladder function (including but not limited to stroke, multiple sclerosis, and Parkinson's disease) or known neurologic pathology that in the opinion of the investigator contributes to bladder dysfunction
  26. Post Void Residual (PVR) > 150 ml on at least 2 occasions
  27. Uncontrolled bleeding disorders
  28. Impassable urethral strictures
  29. Vaginal delivery or Cesarean section within 3 months prior to the screening/baseline visit
  30. Any other condition, which, in the opinion of the investigator, would make the subject not a suitable candidate for the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
314 participants (estimated)

Study arms

  • Experimental
    NASHA Dx

    Investigational device

    Device: NASHA Dx

  • Active comparator
    Bulkamid

    Control device

    Device: Bulkamid

Interventions

  • DeviceNASHA Dx

    The NASHA Dx Urethral Bulking System comprises three components; NASHA Dx SUI Injectable Gel, the NASHA Dx SUI Needle and the Uro-BK Delivery Device. NASHA Dx Injectable Gel is a sterile, injectable bulking agent composed of microspheres of cross-linked dextran ("dextranomer," 50 mg/ml) suspended in a carrier gel of non-animal, stabilized hyaluronic acid (NASHA, 17 mg/ml). The dextranomer microspheres range in diameter from 80 to 250 microns (average diameter approximately 130 microns). NASHA Dx Injectable Gel is provided in a pre-filled single use, 1 ml syringe. The syringe is equipped with a tip cap, plunger, and plunger rod. The syringe is terminally sterilized. The injection needle to be used is the NASHA Dx SUI Needle, a 12cm, 23G extra-thin wall stainless steel cannula with markings at 1 cm and 2 cm from the tip, attached to a styrene-butadiene copolymer Luer-lock hub.

  • DeviceBulkamid

    Bulkamid Urethral Bulking System (i.e., "Bulkamid") is a permanently implanted, non-resorbable, injectable, transparent, hydrogel for urethral bulking. Bulkamid hydrogel consists of cross-linked polyacrylamide (2.5% w/w) and water (97.5% w/w), which is supplied sterile in 1 ml pre-filled syringes. It is intended to be injected with the sterile 23G x 12cm needle using a Bulkamid Rotatable Sheath. Bulkamid is a commercially available device (P170023) indicated for urethral injection for the treatment of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) due to intrinsic sphincter deficiency (ISD). Instructions for use provided by the manufacturer should be consulted for warnings/precautions, known potential risks, and injection procedure. Bulkamid was selected as the control device for this study because it is the market leader in injectable urethral bulking agents, and hence is the standard of care in the US.

07

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    At least a 50% reduction from baseline to 12 months post-treatment in urine leakage, as documented by the 24-hour pad weight test.

    Time frame: 12 months

  2. Primary Safety Endpoint

    The incidence of all adverse events (AEs) through the 12-month follow-up visit after the final injection.

    Time frame: 12 months

Secondary outcomes

  1. Proportion of subjects with at least a 50% reduction from baseline in daily number of incontinence episodes

    Documented via bladder diary

    Time frame: 12 months

  2. Change from baseline in Urogenital Distress Inventory-Short Form (UDI-6) score

    UDI-6 is a validated 6 item questionnaire that evaluates three main symptom categories: irritative (urgency/frequency), stress (activity related leakage), and obstructive/discomfort (voiding difficulties and pain).

    Time frame: 12 months

  3. Change from baseline in Incontinence Impact Questionnaire, Short Form (UIQ-7) score

    UIQ-7 is medical assessment tool that measures how urinary incontinence affects quality of life and daily activities.

    Time frame: 12 months

  4. Patient Global Impressions Improvement (PGI-I) responder rate

    Based on the subject perception of effectiveness ("somewhat improved," "much improved" or "very much improved")

    Time frame: 12 months

  5. Proportion of subjects dry according to the 24-hr. pad test

    i.e., ≤ 4g leakage

    Time frame: 12 months

  6. Change from baseline in the average daily number of incontinence episodes

    Based on bladder diary (stress, urgency, and all urinary incontinence episodes).

    Time frame: 12 months

  7. Proportion of subjects with no SUI episodes

    Based on bladder diary.

    Time frame: 12 months

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: Yes — Data sets of de-identified data underlying the results reported in the published article will be provided. Additionally, the protocol and consent documents will be available. These data will be available six months after publication. Data will be obtained from the corresponding author.

Supporting information: Study protocol, Informed consent form

Time frame: IPD and supporting data will be available starting 6 months after publication. The data will be available for 2 years.

Access criteria: Qualified academic or clinical investigators with valid scientific research proposal may have access to these data and can contact the corresponding author.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 41 industry-sponsored interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 53. This study's planned 12 months is below that.

Counting every sponsor, half of 267 studies reached it within 19 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07850804
Lead sponsor
Palette Life Sciences, Inc.
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Cliff Kline
Contact
cliff.kline@teleflex.com
805-456-9653

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion